Bristol-Myers Squibb and Pfizer have presented the results of the Phase III trial to compare apixaban (Eliquis) to enoxaparin in acutely ill medical patients.

In the study, patients randomised to apixaban received daily injections of enoxaparin placebo for a minimum of 6 days and patients randomised to enoxaparin received apixaban placebo tablets for 30 days.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It was found that the apixaban arm had a 13% lower rate of events than enoxaparin followed by placebo.

The primary efficacy endpoint occurred in 2.71% of patients in the apixaban group compared to 3.06% in the enoxaparin group.

Apixaban is currently being evaluated in ongoing trials for the treatment of recurrent venous thromboembolism, in the Phase III Amplify and Amplify-Ext trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact